Investors
OMX Stockholm
( %)
HNSA SEK
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Press releases
Our latest press releases
Hansa Biopharma participating in Pareto Securities’ 17th Annual Healthcare Conference 2026
27/08/2026
Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
Regulatory press release
21/08/2026
Hansa Biopharma Announces Confidential Submission of Draft Registration Statement to the SEC to allow for a potential Listing of ADSs in the United States
Regulatory press release
21/08/2026
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
18/08/2026
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
